STSA Key Statistics, Chart & Performance
The current stock price of STSA is 1.1 USD. In the past month the price increased by 2.8%. In the past year, price decreased by -67.46%.
STSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About STSA
Company Profile
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 25 full-time employees. The company went IPO on 2019-09-13. The firm is focused on developing a therapeutic product for the acute treatment of migraine. The firm's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.
Company Info
Satsuma Pharmaceuticals Inc
4819 Emperor Boulevard, Suite 340
Durham NORTH CAROLINA 64080 US
CEO: John Kollins
Employees: 25
Phone: 14155050809.0
Satsuma Pharmaceuticals Inc / STSA FAQ
What does STSA do?
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 25 full-time employees. The company went IPO on 2019-09-13. The firm is focused on developing a therapeutic product for the acute treatment of migraine. The firm's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.
Can you provide the latest stock price for Satsuma Pharmaceuticals Inc?
The current stock price of STSA is 1.1 USD. The price decreased by -0.9% in the last trading session.
Does STSA stock pay dividends?
STSA does not pay a dividend.
What is the ChartMill technical and fundamental rating of STSA stock?
STSA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about Satsuma Pharmaceuticals Inc (STSA) stock?
11 analysts have analysed STSA and the average price target is 2.04 USD. This implies a price increase of 85.45% is expected in the next year compared to the current price of 1.1.
What sector and industry does Satsuma Pharmaceuticals Inc belong to?
Satsuma Pharmaceuticals Inc (STSA) operates in the Health Care sector and the Pharmaceuticals industry.
STSA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to STSA. When comparing the yearly performance of all stocks, STSA is a bad performer in the overall market: 86.86% of all stocks are doing better.
STSA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to STSA. STSA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
STSA Financial Highlights
Over the last trailing twelve months STSA reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS decreased by -12.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
STSA Forecast & Estimates
11 analysts have analysed STSA and the average price target is 2.04 USD. This implies a price increase of 85.45% is expected in the next year compared to the current price of 1.1.